Overview

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of NV-5138 in adults with TRD
Phase:
Phase 2
Details
Lead Sponsor:
Navitor Pharmaceuticals, Inc.
Collaborator:
Supernus Pharmaceuticals, Inc.